1. Home
  2. ELVN vs DMLP Comparison

ELVN vs DMLP Comparison

Compare ELVN & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • DMLP
  • Stock Information
  • Founded
  • ELVN 2016
  • DMLP 2003
  • Country
  • ELVN United States
  • DMLP United States
  • Employees
  • ELVN N/A
  • DMLP 27
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • DMLP Oil & Gas Production
  • Sector
  • ELVN Health Care
  • DMLP Energy
  • Exchange
  • ELVN Nasdaq
  • DMLP Nasdaq
  • Market Cap
  • ELVN 1.2B
  • DMLP 1.2B
  • IPO Year
  • ELVN 2020
  • DMLP N/A
  • Fundamental
  • Price
  • ELVN $19.72
  • DMLP $25.51
  • Analyst Decision
  • ELVN Strong Buy
  • DMLP
  • Analyst Count
  • ELVN 5
  • DMLP 0
  • Target Price
  • ELVN $41.20
  • DMLP N/A
  • AVG Volume (30 Days)
  • ELVN 421.4K
  • DMLP 108.7K
  • Earning Date
  • ELVN 08-13-2025
  • DMLP 10-30-2025
  • Dividend Yield
  • ELVN N/A
  • DMLP 12.62%
  • EPS Growth
  • ELVN N/A
  • DMLP N/A
  • EPS
  • ELVN N/A
  • DMLP 1.71
  • Revenue
  • ELVN N/A
  • DMLP $161,859,000.00
  • Revenue This Year
  • ELVN N/A
  • DMLP N/A
  • Revenue Next Year
  • ELVN $25.00
  • DMLP N/A
  • P/E Ratio
  • ELVN N/A
  • DMLP $14.83
  • Revenue Growth
  • ELVN N/A
  • DMLP 4.04
  • 52 Week Low
  • ELVN $13.30
  • DMLP $24.01
  • 52 Week High
  • ELVN $30.03
  • DMLP $34.88
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 47.40
  • DMLP 52.10
  • Support Level
  • ELVN $18.80
  • DMLP $24.50
  • Resistance Level
  • ELVN $21.30
  • DMLP $25.60
  • Average True Range (ATR)
  • ELVN 0.99
  • DMLP 0.45
  • MACD
  • ELVN -0.06
  • DMLP 0.16
  • Stochastic Oscillator
  • ELVN 36.80
  • DMLP 88.68

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.

Share on Social Networks: